ReviewInternational journal of clinical oncology2026
Statistics and epidemiology of inflammatory bowel disease-associated colorectal neoplasia.
Review in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Berberine in Inflammatory Bowel Disease: Integrative Regulation of the Microbiota-Immune-Barrier Axis.International journal of molecular sciences · 2026Review
- Review
- RHOA at the intersection of inflammation-driven and sporadic colorectal cancer.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), are associated with an increased risk of intestinal neoplasia, representing a major long-term complication of chronic inflammation. This review summarizes the recent epidemiological trends and clinicopathological features of IBD-associated colorectal cancer (CRC) and dysplasia in UC and CD. In UC, the cumulative risk of CRC has declined in recent decades, possibly reflecting improvements in medical management and surveillance strategies. However, long disease duration, extensive colitis, concomitant primary sclerosing cholangitis, prior dysplasia, and family history of CRC remain major risk factors. UC-associated neoplasia (UCAN) typically presents as flat lesions with indistinct margins, often accompanied by surrounding dysplasia and frequently exhibits multifocal or infiltrative histological features. The prognosis of UCAN is reportedly poorer than that of sporadic CRC, particularly in advanced stages. In CD, although the overall incidence of neoplasia is lower, the relative risk of colorectal and small intestinal cancer remains significantly higher than in the general population. Geographic variations are notable, with anorectal and fistula-associated carcinomas being most prevalent in East Asia. Risk factors for CD-associated neoplasia (CDAN) include long-standing and early-onset disease, extensive colonic involvement, strictures, and a family history of CRC. Survival outcome of CDAN is worse than that of sporadic CRC, with a higher local recurrence rate. IBD-associated intestinal neoplasia exhibits distinct epidemiological and clinicopathological profiles compared with sporadic CRC. Recent nationwide multicenter studies from Japan provide important insights into UCAN and CDAN, underscoring the importance of region-specific understanding to optimize surveillance and management strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.